spacer
home > epc > spring 2009 > beyond technology
PUBLICATIONS
European Pharmaceutical Contractor

Beyond Technology

As electronic data capture (EDC) is becoming the standard for clinical trials, CROs are under pressure to offer this system and carry out projects that competitively meet time, cost and quality demands. Decisions about the choice of EDC partner must take the sponsor’s interests into account in order to establish an efficient collaboration. EDC vendors are advised to offer special programmes for this purpose.

STRATEGIC EDC PARTNERSHIPS

According to Thomson CenterWatch, the proportion of EDC studies in 2007 exceeded the 40 per cent mark for the first time, with respect to all clinical studies commissioned worldwide (1). Furthermore, it is predicted that this technology will become the standard by 2010. Since further prognoses indicate that the market tends towards standardisation of EDC systems, many CROs choose not to develop their own system and instead work together with specialised EDC vendors.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Claudia Horneck is the Director PR/Promotion of clinIT AG, but also works as a selfemployed Consultant working closely with pharmaceutical contract research organisations. She received her Masters in German Literature, Linguistics and Philosophy from the Albert-Ludwigs University, Freiburg, Germany. Prior to her position at clinIT AG, Claudia held the positions of Head of Sales Administration and Customer Relations Manager at Thomae & Partner AG, Freiburg.

spacer
Claudia Horneck
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PPMA Group Industry Awards 2019

PPMA Group is today issuing a ‘Final Call for Entries’ to the 2019 PPMA Group Industry Awards. All companies within the packaging and processing sector are invited to submit their FREE submission by the deadline of 17 July 2019.
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement